More on aprepitant for erlotinib-induced pruritus

New England Journal of Medicine

Volumn 364, Issue 5, 2011, Pages 486-487

  Gerber, Peter Arne ^a   Buhren, Bettina Alexandra ^a   Homey, Bernhard ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; NEUROKININ 1 RECEPTOR; SUBSTANCE P;

CANCER PATIENT; CELL ACTIVATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; MAST CELL; MEDIATOR; NEOPLASM; PRIORITY JOURNAL; PRURITUS; SKIN;

EID: 79551570675     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1013027     Document Type: Letter

References (3)

1. Levêque D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010;363:1680-1.
2. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010;363:397-8.
3. Gerber PA, Buhren BA, Cevikbas F, Bölke E, Steinhoff M, Homey B. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 2010;63:163-5.